By Counterforce Health Team in Oxbryta (voxelotor) —

Oxbryta (Voxelotor) Coverage by Blue Cross Blue Shield in Illinois: 2024 FDA Withdrawal Impact and Alternative Options

Answer Box: Oxbryta Coverage Status in Illinois

Oxbryta (voxelotor) was withdrawn from the US market by FDA in September 2024 due to safety concerns. Blue Cross Blue Shield of Illinois and all insurers now automatically deny coverage as the drug is no longer FDA-approved. No appeals or bridge coverage are possible. If you were taking Oxbryta, contact your hematologist immediately to transition to alternative sickle cell disease treatments like hydroxyurea, crizanlizumab (Adakveo), or L-glutamine (Endari). Illinois Department of Insurance can help with coverage questions for approved alternatives.

Table of Contents

  1. What Happened to Oxbryta Coverage
  2. Why FDA Withdrew Oxbryta
  3. Current Coverage Status with Blue Cross Blue Shield Illinois
  4. Alternative Sickle Cell Disease Treatments
  5. Getting Coverage for Alternative Medications
  6. Illinois Appeal Rights for Approved Drugs
  7. Patient Support Resources
  8. FAQ

What Happened to Oxbryta Coverage

In September 2024, Pfizer voluntarily withdrew all batches of Oxbryta (voxelotor) from the global market following new safety data. The FDA issued a safety alert instructing immediate discontinuation after postmarketing studies showed increased rates of vaso-occlusive crises and deaths in treated sickle cell patients.

Impact on Insurance Coverage:

  • All insurance plans, including Blue Cross Blue Shield of Illinois, immediately stopped covering Oxbryta
  • No new prescriptions can be filled
  • No appeals process exists since the drug lacks FDA approval
  • Patients must transition to alternative therapies
Important: If you're currently taking Oxbryta, stop immediately and contact your sickle cell specialist. Do not attempt to obtain the medication through any source, as safety concerns led to the complete withdrawal.

Why FDA Withdrew Oxbryta

The withdrawal followed confirmatory clinical trial data showing that the benefits of Oxbryta no longer outweighed the risks. Key safety findings included:

  • Increased frequency of vaso-occlusive crises (painful sickle cell episodes)
  • Higher mortality rates in treated patients
  • Safety profile that deteriorated with longer-term use

Pfizer's official statement confirmed the voluntary withdrawal was based on an unfavorable benefit-risk profile identified in ongoing studies.

Current Coverage Status with Blue Cross Blue Shield Illinois

Blue Cross Blue Shield of Illinois (BCBSIL), part of Health Care Service Corporation (HCSC), follows standard industry practice for withdrawn medications:

Coverage Policy:

  • Automatic denial of all Oxbryta claims since September 26, 2024
  • No prior authorization forms accepted
  • No compassionate use or bridge therapy available
  • Claims processing systems updated to reject all voxelotor NDCs

What This Means for Patients:

  • Outstanding prescriptions cannot be filled
  • Insurance will not reimburse any Oxbryta costs
  • Pharmacy benefit managers have removed the drug from all formularies

Counterforce Health helps patients navigate complex medication coverage situations, but in this unique case of FDA withdrawal, no coverage appeals are possible for Oxbryta itself. However, our platform can assist with securing coverage for alternative sickle cell disease treatments.

Alternative Sickle Cell Disease Treatments

Several FDA-approved options remain available for sickle cell disease management:

First-Line Treatments

Hydroxyurea (Droxia, Hydrea, Siklos)

  • Reduces vaso-occlusive crises and acute chest syndrome
  • Generally well-covered by BCBSIL with minimal prior authorization requirements
  • Requires regular blood monitoring

Newer Targeted Therapies

Crizanlizumab (Adakveo)

  • IV infusion to prevent vaso-occlusive crises
  • Requires prior authorization with BCBSIL
  • Must be prescribed by hematologist
  • Coverage criteria typically require ≥2 crises in past year

L-glutamine (Endari)

  • Oral powder to reduce complications
  • Prior authorization required for patients ≥5 years old
  • Step therapy may apply (try hydroxyurea first)

Advanced Therapies

Gene and Cell Therapies (Lyfgenia, Casgevy)

  • Reserved for severe cases at specialized centers
  • Extensive prior authorization requirements
  • High-cost management protocols apply

Getting Coverage for Alternative Medications

Step-by-Step: Securing Alternative Treatment Coverage

  1. Confirm Your Diagnosis Documentation
    • Ensure your medical records clearly document sickle cell genotype (HbSS, HbSC, etc.)
    • Gather recent lab results and crisis history
  2. Work with a Sickle Cell Specialist
    • BCBSIL often requires prescriptions from hematologists for newer therapies
    • Specialist documentation strengthens prior authorization requests
  3. Submit Prior Authorization Early
    • Use BCBSIL's online portal or provider phone line
    • Allow 2-5 business days for standard reviews
    • Request expedited review for urgent transitions
  4. Document Medical Necessity
    • History of vaso-occlusive crises (frequency and severity)
    • Prior treatment failures or contraindications
    • Current clinical status and treatment goals

Common Prior Authorization Requirements

Medication Age Requirement Crisis History Prescriber Step Therapy
Hydroxyurea Any age Not required Any provider None
Crizanlizumab ≥12 years ≥2 crises/year Hematologist May require hydroxyurea trial
L-glutamine ≥5 years Varies Hematologist Often requires hydroxyurea trial

Illinois Appeal Rights for Approved Drugs

If BCBSIL denies coverage for an approved alternative medication, Illinois provides strong patient appeal rights:

Internal Appeal Process

  • Timeline: Submit within 180 days of denial
  • Decision: BCBSIL has 15 business days for pre-service requests
  • Required: Use insurer's grievance forms and attach supporting documentation

External Review Process

Under the Illinois Health Carrier External Review Act:

  • Deadline: File within 4 months of final denial
  • Process: Independent physician reviewer evaluates medical necessity
  • Timeline: Decision within 45 days maximum
  • Cost: Free to patients
  • Binding: Insurer must comply with favorable decisions
Illinois-Specific Advantage: You can request external review after 30 days if BCBSIL hasn't responded to your internal appeal for ongoing care needs.

How to File External Review:

  1. Complete Illinois Department of Insurance external review form
  2. Attach denial letters and medical records
  3. Submit to Illinois DOI within deadline
  4. Independent Review Organization (IRO) conducts medical review

Getting Help with Appeals

  • Illinois Department of Insurance: (877) 527-9431
  • Illinois Attorney General Health Care Helpline: (877) 305-5145
  • Counterforce Health: Provides evidence-backed appeal assistance for approved medications

Patient Support Resources

Financial Assistance Programs

Manufacturer Patient Assistance:

  • Novartis (Adakveo): Patient support program with copay assistance
  • Emmaus Life Sciences (Endari): Financial assistance for eligible patients

Foundation Support:

  • Patient Advocate Foundation
  • National Organization for Rare Disorders (NORD)
  • Sickle Cell Disease Association of America

Clinical Resources

Finding Specialists:

  • American Society of Hematology provider directory
  • Sickle Cell Disease Association of America center locator
  • BCBSIL provider directory with hematology filter
From Our Advocates: We've seen patients successfully transition from Oxbryta to alternative therapies when their care team documents the medical necessity clearly and submits comprehensive prior authorization requests. The key is working closely with a sickle cell specialist who understands both the clinical rationale and insurance requirements for each alternative medication.

FAQ

Q: Can I still get Oxbryta through any insurance plan in Illinois? A: No. The FDA withdrawal means no insurance plan in the United States covers Oxbryta. The drug is no longer manufactured or distributed.

Q: What if I was stable on Oxbryta and don't want to switch? A: Unfortunately, continuing Oxbryta is not medically recommended or legally possible. The FDA withdrawal was based on safety data showing increased risks that outweigh benefits. Work with your hematologist to find the best alternative.

Q: How long does BCBSIL prior authorization take for alternative SCD medications? A: Standard prior authorization decisions typically take 2-5 business days after BCBSIL receives complete documentation. Expedited reviews are available for urgent medical needs.

Q: Do I need to try hydroxyurea before getting coverage for newer medications? A: Many BCBSIL policies include step therapy requirements, meaning you must try and fail (or have contraindications to) hydroxyurea before accessing medications like crizanlizumab or L-glutamine. Your hematologist can request exceptions based on medical necessity.

Q: What if my current medication isn't working after switching from Oxbryta? A: Document the treatment response (or lack thereof) and work with your specialist to request authorization for alternative therapies. BCBSIL must cover medically necessary treatments for your condition.

Q: Can I appeal to get Oxbryta covered as a formulary exception? A: No. Formulary exceptions only apply to FDA-approved medications. Since Oxbryta has lost FDA approval, no appeal mechanism exists.

Q: Are there any legal remedies for patients harmed by the Oxbryta withdrawal? A: Some law firms are investigating potential compensation claims. Consult with legal counsel if you believe you were harmed by Oxbryta treatment.

Q: How do I find current BCBSIL formulary information for SCD medications? A: Check your plan's most recent formulary on the BCBSIL website. Formularies are updated monthly and changes can occur throughout the year with proper notice.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider about treatment decisions and your insurance plan documents for specific coverage details. Insurance policies and drug approvals can change; verify current status with official sources before making healthcare decisions.

For complex insurance coverage challenges with approved medications, Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals that align with payer policies and clinical guidelines.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.